Reshaping the gut microbiome can boost chemotherapy delivery to tumors
A new study led by researchers at The University of Texas MD Anderson Cancer Center has identified a way to reshape the gut microbiome that can enhance the delivery of certain chemotherapies to tumors, offering a potential strategy to make nanoparticle-based cancer drugs more effective.
A new study from The University of Texas MD Anderson Cancer Center has found that altering the gut microbiome can improve the effectiveness of chemotherapy drugs for cancer patients. Researchers led by Betty Kim, M.D., Ph.D., and Jennifer Wargo, M.D., examined the impact of reshaping the gut bacteria on the delivery of nanoparticle-based chemotherapy drugs.
In preclinical models, administering a short course of antibiotics to selectively reduce certain gut bacteria roughly doubled the time that these drugs remained in circulation, increased their accumulation in tumors, and improved survival across multiple cancer types. This effect was shown to be driven by the microbiome itself, rather than the immune system, indicating that microbiome-directed strategies could be a viable approach to enhancing chemotherapy delivery.
The study highlights the importance of the host's biology, specifically the gut microbiome, in the pharmacokinetics and therapeutic response to nanoparticle-based chemotherapy. The findings underscore the potential for microbiome-targeted approaches to improve cancer treatment, offering a new strategy to boost the effectiveness of nanoparticle-based drugs.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
